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ABSTRACT
The adrenergic system plays a major role in the regulation of
the contractility of the uterus during pregnancy. This study
investigated the role of the a1A-adrenergic receptor (AR) in this
regulation. The use of partial phosphorothioate antisense oli-
godeoxynucleotides (AONs) permitted the sequence-selective
inhibition of AR gene expression. AONs were injected together
with a cationic liposomal carrier agent into the post partum rat
uterus. Incubation for 12 or 24 h with the most effective AON
(480-AON) caused a 58.7 or 53.0% inhibition, respectively, of
the expression of the a1A-AR density, whereas incubation for
36 or 48 h resulted in only a 38.8 or 26.7% inhibition, respec-
tively. The decrease of the a1A-AR density by 480-AON was
demonstrated by Western blot analysis and a radioreceptor
binding assay on rat uterus preparations 24 h after delivery. The
changes in the contractility of the uterus after AON treatment
were measured on isolated rat uterine tissue by electric field
stimulation. The significant decrease in the ability of the uterus
to contract was indicated by the area under the curve method.
The electric field studies revealed that the specific a1A-blockers
5-methylurapidil and WB 4101 inhibited the rhythmic contrac-
tion by about 74 and 70% in the control uteri and by 25 and
20% in 480-AON–treated uteri, respectively. The curves for the
b-mimetic (terbutaline) and a1D-antagonist (BMY7370) inhibi-
tors were unchanged after 480-AON treatment of the uteri.
These results suggest the importance of the a1A-AR in the
tocolytic effect exerted by the a1-antagonist, although high
concentrations of antagonists can not exclude the role of a1D-
ARs, too. Additionally, these prove that the knockdown trans-
formation by AONs offers a useful animal model for the inves-
tigation of receptors controlling the function of uterine tissue.
The extent of the contribution of the a1A-adrenergic recep-
tors (a1A-ARs) in the regulation of uterine contractility re-
mains an open question. Our research was motivated by the
problem of tocolysis (inhibition of uterine contraction during
labor), which has not been adequately solved. The adrenergic
part of the autonomic nervous system plays an important
role in the regulation of the motor activity of the uterus
(Borda et al., 1997). The spontaneous contractility of the
uterine muscle is controlled by the a-ARs, which mediate
uterine contraction (Vallieres et al., 1978; Hoffman et al.,
1981; Rexroad, 1981), and by the b-ARs, which mediate uter-
ine relaxation (Levin et al., 1980; Tanfin-Tougui et al., 1981).
It has been proved that a-adrenergic antagonists induce a
significant decrease in the uterine activity of the rat, both in
vitro and in vivo (Zupko´ et al., 1997; Ga´spa´r et al., 1998),
similar to the effects of b-agonists. Additionally, it has been
found that at the end of pregnancy, the a1/b-adrenoceptor
ratio of the rat uterus is increased in parallel with the in-
crease in contractility (Zupko´ et al. 1998).
It is known that the number of a1A-ARs is significantly
increased in the rat myometrium at term (Legrand et al.,
1987; Limon-Boulez et al., 1997). The extent of their contri-
bution to the regulation of uterine contractility remains an
open question. Before the synthesis of uterus-selective
a1A-AR antagonists, the role of these receptors in uterine
contractility should be investigated. The antisense oligode-
oxynucleotides (AONs) provide an excellent possibility for
such studies.
The antisense effect (i.e., the selective inhibition of gene
expression by antisense RNA, DNA or oligonucleotides)
opened up new possibilities for the selective manipulation of
living functions. A series of techniques have been developed
to exploit their uses. The direct injection of antisense RNA or
transiently expressed DNA vectors into the cytoplasm pro-
vides the most straightforward approach, but has several
drawbacks and limitations. The procedure for generating
stable transgenic species, carrying inversely fused genes,
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controlled by tissue-specific or inducible promoters is a solu-
tion to these problems, but demands appreciable time and
labor. The use of AONs led to a real alternative to these
methods. Because of their obvious potential and attractive
simplicity, huge efforts have been made to develop effective
AONs, but several barriers must be overcome before their
successful therapeutic application in human diseases. The
use of AONs as a nucleotide sequence-selective research tool
involves far fewer problems, and has, in many instances,
proved valuable for the elucidation of complex gene func-
tions.
The aim of the study was to develop an a1A-AR “knock-
down” transformed animal model, involving the use of AONs,
to study the role of the a1A-ARs in the regulation of the
contractility of the rat uterus in pregnancy. The efficiency of
a1A-AR antisense inhibition was indicated by a radioligand
receptor binding assay and Western blot analysis. Electric
field stimulation was applied to test the pharmacological
reactivity of the post partum-isolated rat uterus.
Materials and Methods
Synthesis of AONs. AONs were synthesized on an Expedite 8909
synthesizer (Perkin-Elmer Biosystems Inc., Norwalk, CT), using sol-
id-supported standard b-cyanoethyl phosphoramidite chemistry at a
nominal scale of 1 mmol. Phosphorothioate linkages were generated
individually at chosen points of the sequence after the coupling step
with tetraethyldithiuram treatment for 15 min. In these cases, the
iodine oxidation step was omitted. Purification was performed on
Poly PAK (Glen Research, Sterling, VA) cartridges according to the
procedure supplied by the manufacturer. The purified product was
converted into the sodium salt on Dowex 50X8 [Na1] resin. Purity
was controlled by anion exchange high-performance liquid chroma-
tography, and proved to be 97 to 98% by absorbance measurements
at 260 nm. None of the impurities exceeded 1% of the total absor-
bance. High-performance liquid chromatography was carried out on
a Vydac 301 VHP column (Vydak, Hesperia, CA) with a gradient of
0 to 0.3 M NaCl in 10 mM Tris-HCl, pH 8.0. The phosphodiester/
phosphorothioate ratio in 480-AON was checked by 31P-NMR spec-
troscopic experiments with a Bruker WM-250 instrument (101.2
MHz, external H3PO4 standard; Bruker, Newark, DE) in D2O and
found to be 11:8. Undesired phosphodiester contamination was below
the detectable limit (3%).
Treatment of Animals with AONs. The AONs were mixed with
DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium
methylsulfate; Roche Molecular Biochemicals, Mannheim, Germany)
and 20% F127 Pluronic gel (Sigma-Aldrich, Budapest, Hungary).
The solution was maintained in liquid form at 4°C before injection.
Postpartum Sprague-Dawley rats (91 rats with weights in the range
180–200 g) under urethane anesthesia (1 g/kg, i.p.) were treated with
AONs 2 to 3 h after labor. An incision was made in the lower
abdomen and AON solution was injected from prechilled syringes
into the luminal space of each uterine horn. Each AON sample was
administered in two steps at two discrete locations along the length
of the horn. The incision was then closed, and the animals were
returned to their cages. Uteri were used for further investigation
24 h after delivery.
Membrane Preparation. The uteri were removed and homoge-
nized in 20 volumes (w/v) of ice-cold buffer (10 mM Tris-HCl, 1 mM
EDTA, 0.6 mM MgCl2, and 0.25 M sucrose, pH 7.4) with an Ultra
Turret T25 (Janke & Kunkel, Staufen, Germany) homogenizer and
the suspension was then filtered on four layers of gauze and centri-
fuged (40,000g, 4°C, 20 min). After centrifugation, the pellet was
resuspended in a 5-fold volume of buffer. The membranes were
stored at 270°C. For Western blot assay, the resulting pellet was
resuspended in lysate buffer (50 mM Tris-HCl, pH 8.0, 0.5% deoxy-
cholate, 1% Triton X-100, 0.1% SDS, 1% phenylmethylsulfonyl fluo-
ride, and 1 mg/ml aprotinin) and stored at 270°C. Protein concen-
tration was determined by the method of Bradford (1976).
Radioreceptor Binding Assays. The frozen membranes were
thawed at room temperature. Radioligand-binding experiments were
carried out on membrane preparations of rat uterus in 50 mM
Tris-HCl buffer, pH 7.4, containing 3 mM MgCl2 and 1 mM ascorbic
acid in a final volume of 300 ml. The concentration of tritiated
prazosin in saturation experiments was varied between 0.1 and 2.5
nM. The reaction mixture contained 100 ml of [3H]prazosin
(PerkinElmer Life Science Products, Hounslow, UK), 100 ml of mem-
brane preparation and 100 ml of 1025 M unlabeled phentolamine
(Sigma-Aldrich) for nonspecific binding, or 100 ml of buffer for total
binding. The concentration of tritiated prazosin was 1.5 nM in dis-
placement studies. The concentrations of unlabeled ligand (prazosin,
WB4101) were varied in the range 1025 to 10212 M. Incubations
began with the addition of the membrane suspension and continued
in a shaking water-bath until a steady state was achieved (30°C, 30
min). The reaction was terminated by rapid filtration on a Brandel
M24R cell harvester (BioMedical Research & Development Labora-
tories Inc., Gaithersburg, MD) through Whatman GF/C filters, and
the residue was washed with three applications of 5 ml of ice-cold
Tris-HCl buffer, pH 7.4. The bound radioactivity was determined in
a HighSafe (Wallac Oy, Turku, Finland) scintillation cocktail in a
Wallac 1409 liquid scintillation counter (Wallac Oy). The total bind-
ing was defined as that measured in the absence of a competing
agent. Nonspecific binding was determined in the presence of 10 mM
unlabeled phentolamine and was about 15% of the total binding. All
assays were carried out at least three times in duplicate, and values
are given as means 6 S.E.M. The binding capacities were analyzed
using the computer program Prism 2.01 (GraphPad Software, San
Diego, CA) with a nonlinear least-squares fitting algorithm. Statis-
tical analyses were performed with the Newman-Keuls analysis of
variance test to assay significant differences in AON-treated uteri.
Western Blot Assay. Protein (20–30 mg per well) was subjected
to electrophoresis on 12.5% SDS polyacrylamide gels in Series Stan-
dard Dual Cooled Units (Bio-Rad, Budapest, Hungary). Proteins
were transferred from gels to nitrocellulose membranes (Schleicher
and Schuell, Dassel, Germany), using a semidry blotting technique
(BioRad). The membranes were blocked with phosphate-buffered
saline (PBS), pH 7.4, containing 1% nonfat dry milk, 0.1% Tween 20,
and 1% polyvinylpyrrolidone overnight at 4°C. After washing, the
blots were incubated for 1 to 3 h, at room temperature, on a shaker
with anti-a1A-AR, a1B-AR, a1D-AR polyclonal antibody (diluted
1:400, Research Diagnostics, Flanders, NJ) in PBS with 1% nonfat
dry milk, 0.1% Tween 20, and 1% polyvinylpyrrolidone. The blots
were washed and incubated with 1:1000 peroxidase-conjugated goat
anti-rabbit IgG (Sigma-Aldrich) in PBS with 0.1% Tween 20. The
antibody binding was detected with an enhanced chemiluminescence
detection system (Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire, UK) and exposed on Kodak X-Omat film (Sigma-
Aldrich). Anti-b-actin monoclonal antibody (Sigma-Aldrich) was
used as a control.
Electric Field Stimulation. Pretreated uteri were removed from
rats 24 h after delivery. Muscle rings 0.5 cm long were sliced from the
uterine horns and mounted vertically between two platinum elec-
trodes in an organ bath containing 10 ml of de Jongh solution (137
mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 12 mM NaHCO3,
4 mM NaH2PO4, 6 mM glucose, pH 7.4). The organ bath was main-
tained at 37°C and carbogen (95% O2/5% CO2) was bubbled through
it. After mounting, the rings were equilibrated for about 1 h before
experiments were undertaken. The initial tension was set at 1.25 g,
which was relaxed to 0.5 g at the end of equilibration. After the
incubation period, rhythmic contractions were elicited by a digital,
programmable stimulator (ST-02; Experimetria Ltd., Budapest,
Hungary), using square pulses with a duration of 200 ms every 60 s
at 40 V. The tension of the myometrial rings was measured with a
strain gage transducer (SG-02; Experimetria, Ltd.) and recorded by
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an ISOSYS Data Acquisition System (Experimetria, Ltd.). Noncu-
mulative concentration-response curves to the selective a1A-receptor
antagonist 5-methylurapidil and WB 4101 (RBI, USA), the a1D-
antagonist BMY7378 (RBI/Sigma, Natick, MA) and terbutaline (Sig-
ma-Aldrich) were constructed in each experiment. Areas under the
curves (AUCs) were evaluated and were analyzed statistically with
the computer program Prism 2.01.
Results
The selection of target sites for AONs was based on theo-
retical modeling and careful optimization. The most probable
secondary structures of a1A-AR mRNA (GenBank accession
no. M60654) were first computed by free energy minimiza-
tion. For this purpose, the computer software mfold (version
3.0) of Zuker and Turner was applied through an Internet
connection (Zuker et al., 1999). With the RNA base-sequence
as input, the computation provided a series of thermodynam-
ically optimal and suboptimal foldings of a1A-AR mRNA.
Single-stranded regions were listed as potential target sites.
The chosen fragments were further screened on the basis of
the general criteria of primer planning and the free energy of
duplex formation. Finally, a set of four AONs was chosen
together with the appropriate control sequences. The AONs
were directed toward different functional regions of the
mRNA: 214-AON against the 59-untranslated region, 480-
AON against the translation-initiation site, and 1834-AON
against the coding region.
To stabilize the oligonucleotides against nucleolytic decom-
position inside the cells, phosphorothioate internucleotide
linkages were incorporated in a sequence-specific manner
according to the principle of minimal modification (Peyman
and Uhlmann, 1996). Two thioate substituents were built in,
on both the 59 and 39 termini, and one was positioned in the
vicinity of each pyrimidine nucleotide on either the 59 or the
39 side. The structures and properties of the AONs used in
the experiments are listed in Table 1. The free energy of
hybridization (i.e., the duplex-forming abilities of all the ex-
amined oligomers) fell into a relatively narrow range. We
have tabulated the melting temperatures (Tm) of the oligo-
nucleotides, which were calculated with a fully complemen-
tary opposite strand and disregarding phosphorothioate sub-
stitutions, as an indication of their comparable
hybridizational energy. With the use of the dose-response
analysis, the effective dose was determined as 50 nmol/200 ml
(Fig. 1).
The changes in the receptor density caused by the AONs
were investigated by radioreceptor binding assays 12, 24, 36,
and 48 h after delivery to establish the optimum time of AON
treatment. In the saturation experiments, the maximum
number of a1A binding sites (Bmax) in the AON-treated rat
uterus was determined. Of the synthesized AONs, 480-AON
reduced the a1A-AR density in a time-dependent fashion com-
pared with the untreated group “C” (Bmax 5 29.05 6 1.27)
and the random oligonucleotide-treated control group “R”
(Bmax 5 29.13 6 1.12) (Fig. 2). The most significant changes
were observed 12 and 24 h after delivery (p , 0.001 in
comparison with the control). Incubation with 480-AON for
12 or 24 h caused a 58.7 or 53.0% inhibition and the Bmax
values under these conditions were 12.04 6 0.86 and 13.69 6
0.42 fmol/mg, respectively. Thirty-six or 48 h after the deliv-
ery, 38.8% (p , 0.001) or 26.7% (p , 0.001) inhibition was
detected, and the a1A-AR density was 17.99 6 0.43 and
21.40 6 0.51 fmol/mg, respectively. No significant changes in
receptor density were found for the other AONs.
The a1A-selective WB4101 identified two a1-adrenergic
binding sites in the nontreated rat uterus, with Kd values of
0.011 and 15.05 nM, whereas in the treated animals, it bound
to only one binding site (Ki 5 36.12 nM) (Fig. 3). In Western
blot analysis, the a1A-AR density was only decreased by
480-AON (Figs. 4 and 5). Representative contraction curves
of control, operated control, DOTAP-treated, 480-mAON–
treated, and 480-sAON–treated uteri display different re-
sponses to electric field stimulation (Fig. 6).
The AUCs of the uterine contractility indicated the signif-
icantly decreased contractility of the 480-AON-treated
uterus as compared with those of the control, the operated
control, the DOTAP-treated control, the 480-mAON–treated
control, and the 480-sAON–treated control (Fig. 7). Addition-
ally, the EFS studies revealed that the specific a1A-blockers
5-methylurapidil and WB 4101 inhibited the rhythmic con-
tractions by about 75 and 70% in the control uteri and 25 and
20% in the 480-AON–treated uteri, respectively. The IC50
values for 5-methylurapidil and WB 4101 in the control uteri
were 3.8 3 1025 and 9.5 3 1026, respectively. In the event of
a mismatched sequence, inhibitions can be experienced only
with high doses, whereas with the scrambled control the
maximum inhibitions corresponded to the untreated control
(Fig. 8, b and c). The inhibition curves of terbutaline and
BMY 7378 remained unchanged for the 480-AON-treated
uteri compared with those of the control (Fig. 8a).
TABLE 1
Oligodeoxynucleotides
Melting temperature was calculated according to the nearest neighbor method at 50 mmol salt concentration (Breslauer et al., 1986) with a fully complemented opposite
strand and disregarding the destabilization effect of phosphorothioate substituents. Subscript “s” in the base sequence denotes phosphorothioate linkage.
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Cloning and pharmacological data have demonstrated that
a1-ARs can be classified into three subtypes: a1A-, a1B-, and
a1D-ARs. The genes for each of the subtypes are expressed in
discrete, tissue-specific patterns (Perez et al., 1994; Price et
al., 1994; Scofield et al., 1995). A major problem as concerns
the determination of the function of each of the a1-AR sub-
types is the paucity of pharmacological tools available to
distinguish among them. To address this question, AONs
were used for the selective blocking of the receptor protein
expression. This may provide an alternative means of study-
ing individual a1-AR subtype functions (Pedro et al., 1998).
AONs are complementary nucleic acid fragments that hy-
bridize to the target sequence within RNA to form a DNA-
RNA duplex, resulting in a blockade of the translation of
mRNA into protein (Akhtar and Agrawal, 1997). One of the
major problems in the application of AONs, for either re-
search or therapeutic purposes, is the selection of the target
sites on the chosen mRNA. To date, most of the effective
molecules have been found on a trial and error basis. This
approach requires much time and effort and involves only a
moderate and varying chance of success (5–15%, which is
effective enough for further evaluation). An often used, reli-
able method is to choose functionally important sites (e.g.,
ribosome-binding, translational-initiation, or splicing sites)
of the RNA. Among the studies that examined one or only a
few AONs, a strong majority targeted the AUG translation-
initiation codon (Tu et al., 1998). The chance of success is
higher at these sites, but targets that are more vulnerable
can be found throughout the RNA. Of 14 AONs that reached
the clinical trial phase, only two are targeted against the
AUG initiation regions (Hogrefe, 2000). The simple strategy
of choosing the thermodynamically most stable duplex-form-
ing sites failed.
Better results were obtained with another approach, which
was based on the secondary structure of the mRNA. A recent
study provided the first clear-cut evidence that the antisense
efficiency depends mainly upon the secondary structure and
accessibility of RNA (Vickers et al., 2000). To improve our
chances of finding effective AONs, we chose the latter ap-
proach. The secondary structure of the mRNA was predicted
by computer modeling, using improved thermodynamic pa-
rameters (Mathews et al., 1999). As potential antisense tar-
get sites, single-stranded loop and hairpin structures were
considered (Vickers et al., 2000; Lima et al., 1992). As further
criteria, the strength of duplex formation and the lack of
strong secondary structures were used. AONs with too low
Tm values (, 35°C) were rejected. Among the oligonucleo-
tides chosen, 480-AON conformed to both the functional and
the secondary structure selection strategy, because it covered
the translation initiation site. This AON was the only one
that displayed a significant inhibitory effect. This result con-
firms the accessibility of the translation initiation site as a
potential antisense target, but the fact that the effective
AON met both criteria, and one very small number of mole-
cules tested does not allow us to draw any conclusion con-
cerning the selection strategy.
Fig. 1. Dose-dependent inhibition response. The rat uteri were treated
with 5, 10, 20, 50, 75, and 90 nmol/200 ml 480-AON. The levels of the
a1A-ARs protein expression were normalized to the levels of b-actin. The
resulting values were plotted as a percentage of levels obtained from
untreated samples. The error bars represent the S.E.M.
Fig. 2. Rate of change of density of maximum number of a1-AR binding
sites (Bmax) and percentage of inhibition, 12, 24, 36, and 48 h after
delivery, compared with untreated (C) and random oligonucleotide-
treated (R) control uteri. Densities were measured as Bmax values in
saturation binding assays with [H3]prazosin. Fifty nanomoles of both
480-AON and the random oligodeoxynucleotide (R) were used, which
significantly (**p , 0.01; ***p , 0.001 versus control, analysis of vari-
ance Newman-Keuls test) decreased the a1- AR density 12 to 48 h after
delivery. (12 versus 24, p . 0.05; 24 versus 36, p , 0.001; 36 versus 48,
p , 0.01).
Fig. 3. The 480-AON induced change in the receptor density investigated
by radioligand receptor binding assay. The concentration of [3H]prazosin
was 1.5 nM and the concentration of the unlabeled ligand was varied
between 1025 and 10212 M. The displacement curves demonstrate the
lack of the a1A-AR subtypes in 480-AON–treated rat uteri. The WB4101
(a1A-AR subtype-selective) binds to a single class of binding sites in the
480-AON–treated rat uterus membrane preparation, whereas it recog-
nizes two binding sites in the nontreated rat uterus preparation; the
high-affinity binding site is identical with the a1A-AR subtype. F,
[3H]prazosin-prazosin displacement (AON-treated rat); f, [3H]prazosin-
WB 4101 displacement (AON-treated rat); , [3H]prazosin-WB 4101 dis-
placement (untreated rat).
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Phosphodiester oligonucleotides were found to be rapidly
degraded inside the cell. Phosphorothioate oligomers with
one sulfur substitution for phosphorus in the nonbridging
position have become a common solution to achieve a longer
biological life-span of the oligos. However, phosphorothioate
oligonucleotides often have nonspecific effects, especially at
higher concentrations (Stein and Krieg, 1998). We applied
the principle of minimal modification, a combination of end-
capping and pyrimidine protection. The end-capping phos-
phorothioate linkages protected the oligomer against exonu-
cleolytic cleavage, whereas the internal phosphorothioate
substitutions in the vicinity of the pyridine nucleotides in-
hibited the endonucleolytic degradation (Uhlmann et al.,
1997). The smallest possible number of modifications was
made and appropriate stabilization was expected. Recent
studies revealed that a higher specificity can be achieved
with partially thioated oligomers than with fully thioated
ones. The liposomal cationic carrier used for functional de-
livery of the oligonucleotides prolonged the antisense effect
substantially, by delaying nucleolytic degradation (Galderisi
et al., 1999).
Three different oligomer controls were used in our experi-
ments to verify the specificity of the AON: 1) a random
control with an arbitrarily chosen nucleotide sequence and
composition, 2) a scrambled control with a conserved base
composition and an altered sequence, and 3) a mismatched
control, in which the base sequence was changed arbitrarily
at a single point. Moreover, untreated and excipient-treated
animals were used as controls.
The effects of AONs in the down-regulation of a1A-AR were
tested at two levels. We studied the decrease in receptor
protein density via Western blot analysis and a radioligand
binding technique and detected the changes in function at a
physiological level with the electric field stimulation tech-
nique (Elmer et al., 1980; Taneike et al., 1999).
The results of the receptor binding studies indicated that
the antisense effect is most expressed 12 and 24 h after
delivery. The density of a1A-ARs in the postpartum rat
uterus reaches a plateau 24 h after delivery. The optimum
duration of treatment was set to 24 h, thereby coinciding
with the maximum effect of AON. The a1A-AR density was
decreased most effectively by one (480-AON) of the four syn-
thesized a1A-AONs, which was in keeping with the literature
data.
The a1A-AR subtype-selective WB4101 binds to high-affin-
ity (a1A-ARs) and low-affinity binding sites in the nontreated
rat uterus membrane preparation. On the other hand, in the
480-AON-treated rat uterus, WB4101 recognizes only a sin-
gle class of binding site, which has the same Ki value as the
inhibition constant of the low-affinity binding site in the
nontreated rat uterus.
The results of the molecular biological studies were sup-
ported by the physiological and pharmacological investiga-
tions, which presented further evidence of the selectivity of
480-AON and proved the importance of the a1A-ARs in the
regulation of the rat uterine contractility.
In the electric field studies, we used direct muscle stimu-
lation, because a denervation process takes place in the rat
uterus during pregnancy (Mustafa, 1988). However, the in-
hibition of the a1A-ARs can be investigated through a block-
ade of the nonsynaptic receptors in the uterus (Ga´spa´r et al.,
1998).
The contractilities of the treated and untreated uteri were
Fig. 4. Changes in a1A-AR (a), a1B-AR (b), and a1D-AR (c) protein expres-
sion of the AON-treated (214, 1834, and 480-AON), postpartum uteri
illustrated by Western blot analysis, as compared with DOTAP-treated
(D) and nontreated (C) uteri. The sequence of oligonucleotides is shown in
Table 1. In this analysis, the density of the a1A-ARs was only significantly
decreased by 480-AON. Samples (50 mg/lane) were subjected to gel elec-
trophoresis on 12.5% polyacrylamide gel. The blot was stripped and
reprobed for b-actin, and a similar intensity was observed in each lane.
Fig. 5. Two different oligomer controls (480-sAON and 480-mAON) and
an untreated control (C) were used to verify the specificity of 480-AON.
480-AON significantly decreased the a1A-AR density. b-actin was used as
a control. 480-sAON, the AON base composition was retained but the
base sequence was mixed; 480-mAON, the AON base sequence contained
an by arbitrary change at one point.
a1a-Adrenergic Receptor and Rat Uterus Contractility 1239
 at A








deduced from their responses to stimuli. The abilities of the
uteri to contract were compared via the AUCs (because of the
lack of an in vivo model) and basic conclusions were drawn as
to the physiological activity of pregnant uterine contractility.
The surgical operation reduced the average of contractions
AUCs from 0.35 to 0.25, whereas the antisense treatment
decreased the average from 0.25 to 0.15. If the changes are
expressed in percentages, it can be said that the surgery
caused a ;28% reduction. However, the antisense treatment
elicited a further 40% decrease in the contractility. It is
thought that urethane anesthesia is responsible for the de-
crease in contractility after surgery because the untreated
controls were not involved in any type of anesthesia. These
values indicate that the a1A-ARs have a significant, although
obviously nonabsolute, role in the contractility.
In pharmacological experiments, we found that the con-
traction inhibitory effects of the specific a1A-AR competitive
antagonists 5-methylurapidil (Gross et al., 1988) and WB
4101 (Michel M et al., 1995) were significantly decreased in
the 480-AON–treated uteri, but the unchanged effects of an
a1D-sympatholytic (BMY 7378) and b-mimetic (terbutaline)
demonstrated that the AON treatment did not affect the
Fig. 6. Representative curves of
control (a) operated control (b),
DOTAP-treated control (c), 480-
AON– (d), 480-mAON– (e) and
480-sAON–treated post partum
uteri contracted by electric field
stimulation.
Fig. 7. Changes in values of AUC for the contractions stimulated by an
electric field. The differences in AUCs between the untreated control (C)
and the operated control (O), the DOTAP-treated control (D), the 480-
mAON–treated control and the 480-sAON–treated control were statisti-
cally significant. The AUC value for the 480-AON–treated uterus was
significantly different (**p , 0.01) from those for the DOTAP-treated
control (D), the operated control (O), the 480-mAON–treated control, and
the 480-sAON–treated control. There was no significant difference be-
tween the operated control (O), the DOTAP-treated control (D), the 480-
mAON–treated control, and the 480-sAON–treated control.
1240 Ducza et al.
 at A








function of the a1D-ARs and b-ARs, suggesting the selectivity
of 480-AON. It seems impossible that the subtype-selective
a1-blockers remain selective even at such a high concentra-
tion, but if the molecules lost their selectivity to the a1-
receptor subtypes, 5-MU should not lose its effectiveness
after the antisense treatment. In parallel, the inhibitory ef-
fect of BMY 7378 should also be changed in the case of
nonselective binding, because the a1A-component of its effect
should be eliminated. Additionally, in our system, the recep-
tor affinity of WB 4101 is four times higher than that of
5-MU, this result coinciding with the literature data by
Yamamoto and Koike (1999), Barbieri et al. (1998), and
Arias-Montano et al. (1996). These results show that the
difference in affinity between WB 4101 and 5-MU remains at
such a high dose.
The decrease in the effects of 5-methylurapidil and WB
4101 in the 480-AON–treated uteri suggests “negative” phar-
macological evidence of the significance of the inhibition of
uterine contractility through the a1A-ARs. The local use of
AONs in the uterus, in an attempt to clarify the role of the
receptors, which influence the uterine contractility, is a new
method in pharmacology. This method was used to develop
an a1A-AR knock-down transformed animal model, which
provided experimental opportunities that were unavailable
with the previously existing pharmacological methods.
In light of these facts, we suppose that the a1A-ARs have an
important role in the contractility, although high concentra-
tions of subtype-selective antagonists were required in con-
tractility studies. However, the role of a1D-ARs can not be
excluded in the control of pregnant uterine contraction.
Fig. 8. Effects of 5-methylurapidil, WB
4101, BMY7378, and terbutaline on
the EFS-stimulated uterine contrac-
tion in the presence of 480-AON (a).
Effects of 5-methylurapidil (b) and WB
4101 (c) on the EFS-stimulated uterine
contraction for the control (C), the
DOTAP-treated control (D), the 480-
mAON-treated control, and the 480-
sAON-treated control. The data are
the averages of the results of six exper-
iments 6 S.E.M.
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